Skip to main content
. Author manuscript; available in PMC: 2010 Nov 1.
Published in final edited form as: Prostaglandins Leukot Essent Fatty Acids. 2009 Oct 22;81(5-6):357–366. doi: 10.1016/j.plefa.2009.09.004

Figure 3. Benzo-LXA4 analogs reduce inflammation in vivo in a dose-dependent fashion.

Figure 3

ATLa, o-[9,12]-benzo-ω6-epi-LXA4, or [9,14]-benzo-ω6-(R/S)-LXA4 were injected by intravenous bolus injection (0.5, 5, 15, 25 or 50 μg kg−1 in 100 μL of sterile saline) via the tail vein of 6-8-wk male FVB mice followed by peritoneal injection of zymosan A (1 mg/1 mL). Peritoneal lavages were collected (2 h) and total leukocytes, PMNs and monocytes were enumerated. Reduction in PMN infiltration was determined by comparison to vehicle control (100 μL of sterile saline). A. Dose-response comparison between ATLa (■) and o-[9,12]-benzo-ω6-epi-LXA4(○). B. Dose-response comparison between ATLa (■) and [9,14]-benzo-ω6-(R/S)-LXA4 (○). Values represent mean ± SEM, n=3-5, *P < 0.0001, §P < 0.05.